This inventor holds 1 USPTO granted patent. Top assignee: Ildong Pharmaceutical Co., Ltd.. Active years: 2026.
Data source: USPTO (United States Patent and Trademark Office) public patent records. Weekly synchronization. How IDiyas builds this profile
Company Filing History:
Years Active: 2026
Title: Tae-Yoon Kim and His Work on Bifidobacterium breve
Introduction
Tae-Yoon Kim is an inventor associated with Ildong Pharmaceutical Co., Ltd. His listed patent concerns a Bifidobacterium breve strain and its potential applications related to dyslipidemia.
Latest Patents
The provided information lists one patent for Kim: “Novel Bifidobacterium breve IDCC 4401 Strain and Its Dead Cell ID-BBR4401 Having Excellent Acid Tolerance and Bile Tolerance and Prophylactic or Therapeutic Effect on Dyslipidemia.” The invention describes a bacterial strain and its dead-cell form, with claimed acid and bile tolerance and potential prophylactic or therapeutic effects on dyslipidemia. The supplied data does not specify the patent’s filing or grant date. Kim is credited with 1 patent in the information provided.
Career Highlights
Kim’s listed patent reflects work in biotechnology and pharmaceutical research, particularly the investigation of probiotic strains and their possible health applications. The provided information identifies Ildong Pharmaceutical Co., Ltd. as his company affiliation.
Collaborations
The supplied data names Min-Goo Kim and Don-Gil Lee as Kim’s coworkers. It does not specify their roles in the patent or the nature of their collaboration.
Conclusion
Tae-Yoon Kim’s listed invention focuses on a Bifidobacterium breve strain and its potential relevance to dyslipidemia, highlighting his connection to pharmaceutical and biotechnology innovation.
Data source: USPTO (United States Patent and Trademark Office) public patent records. Weekly synchronization. How IDiyas builds this profile